Completion of the Pivotal Phase 3 Trial for Olanzapine LAI in Schizophrenia Conducted by Teva Pharmaceuticals

February 10, 2025 at 02:00 AM EST

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

Medincell to receive a $5 million development milestone payment from Teva with SOLARIS study completion (last patient last visit)

Richard Malamut, Chief Medical Officer at Medincell comments: “Our partner is advancing the clinical development of the olanzapine LAI with plans for regulatory submission in the US. This structured approach highlights a strong commitment to addressing a critical unmet need. As a result of Medincell technology, a long-acting injectable formulation of olanzapine may be widely used by patients with schizophrenia.”

Medincell (Paris:MEDCL):

Contacts

David Heuzé

Head of Corporate and Financial Communications, and ESG

david.heuze@Medincell.com / +33 (0)6 83 25 21 86

Grace Kim

Head of US Financial Strategy & IR

grace.kim@Medincell.com / +1 (646) 991-4023

Nicolas Mérigeau/ Arthur Rouillé

Media Relations

Medincell@newcap.eu / +33 (0)1 44 71 94 94

Louis-Victor Delouvrier/Alban Dufumier

Investor Relations France

Medincell@newcap.eu / +33 (0)1 44 71 94 94

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.